The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Chondroprotective effect of intraarticular injections of interleukin‐1 receptor antagonist in experimental osteoarthritis. Suppression of collagenase‐1 expression
Abstract
Objective. To investigate the in vivo effect of recombinant human interleukin‐1 receptor antagonist (rHuIL‐1Ra) on the development of lesions and the expression of metalloproteases in the canine experimental osteoarthritis (OA) model. Methods. The right anterior cruciate ligament was sectioned percutaneously in 3 groups of dogs. The control group (n = 5) received an intraarticular injection of sterile physiologic saline (1 ml) twice weekly for 4 weeks starting on the day of surgery. The remaining 2 groups received intraarticular injections of either 2 mg (n = 6) or 4 mg (n = 5) rHuIL‐1Ra in 1 ml of physiologic saline according to the same schedule as the first group. All dogs were killed 4 weeks after surgery. The macroscopic appearance of femoral condyle osteophytes and the size and severity of cartilage lesions on femoral condyles and tibial plateaus were evaluated, as were the histologic features of cartilage and synovial membrane. Levels of collagenase‐1 and stromelysin‐1 messenger RNA expression in cartilage and synovium were determined by Northern blotting. Results. Recombinant human IL‐1Ra exerted a dose‐dependent protective effect on the development of osteophytes and cartilage lesions in vivo. Treatment with rHuIL‐1Ra reduced the incidence (saline‐treated group 70%, 2 mg rHuIL‐1Ra–treated group 42%, 4 mg rHuIL‐1Ra–treated group 20%) and size (saline‐treated group 2.3 ± 0.7 mm [mean ± SEM], 2 mg rHuIL‐1Ra–treated group 0.7 ± 0.3 mm, 4 mg rHuIL‐1Ra–treated group 0.5 ± 0.3 mm) of femoral condyle osteophytes. In addition, a dose‐dependent decrease in the size (saline‐treated group 24.40 ± 8.17 mm 2, 2 mg rHuIL‐1Ra–treated group 20.90 ± 8.01 mm 2, 4 mg rHuIL‐1Ra–treated group 7.70 ± 5.16 mm 2) and the grade (0–4 scale; saline‐treated group 1.20 ± 0.29, 2 mg rHuIL‐1Ra–treated group 1.00 ± 0.26, 4 mg rHuIL‐1Ra–treated group 0.30 ± 0.21) of the tibial plateau cartilage lesions was found, with a significant difference (P < 0.04) reached only with 4 mg rHuIL‐1Ra. Similarly, the histologic lesions in dogs treated with 4 mg rHuIL‐1Ra (Mankin scale; mean ± SEM 2.95 ± 0.53) were significantly less severe (P < 0.002) compared with those in the saline‐treated group (4.95 ± 0.54). Importantly, rHuIL‐1Ra treatment led to a significant reduction (P < 0.005) of collagenase‐1 expression in OA cartilage. Conclusion. This study demonstrated that intraarticular injections of rHuIL‐1Ra can protect against the development of experimentally induced OA lesions. This effect could result, at least in part, from a reduction of collagenase‐1 expression. However, other catabolic processes involved in the degradation of OA cartilage may also be affected.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MANKIN, H. J., DORFMAN, H., LIPPIELLO, L., & ZARINS, A. (1971) · The Journal of Bone & Joint Surgery · doi:10.2106/00004623-197153030-00009 · Cited by 1,963
Charalambous, C. P. (2014) · Classic Papers in Orthopaedics · doi:10.1007/978-1-4471-5451-8_97 · Cited by 1,835
Tso, J. Y., Sun, X.-H., Kao, T.-H., Reece, K. S., & Wu, R. (1985) · Nucleic Acids Research · doi:10.1093/nar/13.7.2485 · Cited by 1,791
Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor
Hannum, C. H., Wilcox, C. J., Arend, W. P., Joslin, F. G., Dripps, D. J., Heimdal, P. L., Armes, L. G., Sommer, A., Eisenberg, S. P., & Thompson, R. C. (1990) · Nature · doi:10.1038/343336a0 · Cited by 1,122
Arend, W. P., & Dayer, J. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380202 · Cited by 891
Interleukin-1 Receptor Antagonist
Arend, W. P. (1993) · Advances in Immunology · doi:10.1016/s0065-2776(08)60535-0 · Cited by 671
Goldberg, G. I., Wilhelm, S. M., Kronberger, A., Bauer, E. A., Grant, G. A., & Eisen, A. Z. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)84605-7 · Cited by 632
Carter, D. B., Deibel, M. R., Dunn, C. J., Tomich, C.-S. C., Laborde, A. L., Slightom, J. L., Berger, A. E., Bienkowski, M. J., Sun, F. F., McEwan, R. N., et al. (1990) · Nature · doi:10.1038/344633a0 · Cited by 601
Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist.
Arend, W. P., Welgus, H. G., Thompson, R. C., & Eisenberg, S. P. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114622 · Cited by 581
MacNaul, K. L., Chartrain, N., Lark, M., Tocci, M. J., & Hutchinson, N. I. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)44894-0 · Cited by 399
Goldring, M. B., Birkhead, J., Sandell, L. J., Kimura, T., & Krane, S. M. (1988) · Journal of Clinical Investigation · doi:10.1172/jci113823 · Cited by 397
van Beuningen, H. M., van der Kraan, P. M., Arntz, O., & van den Berg, W. B. (1994) · PubMed · Cited by 355
Brandt, K. D., Myers, S. L., Burr, D., & Albrecht, M. (1991) · Arthritis & Rheumatism · doi:10.1002/art.1780341214 · Cited by 339
Arend, W. P., Joslin, F. G., & Massoni, R. J. (1985) · The Journal of Immunology · doi:10.4049/jimmunol.134.6.3868 · Cited by 322
Amelioration of established murine collagen-induced arthritis with anti-IL-1 treatment
VAN DEN BERG, W. B., JOOSTEN, L. A. B., HELSEN, M., & VAN DE LOO, F. A. J. (2008) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.1994.tb06517.x · Cited by 251
Reduction of the severity of canine osteoarthritis by prophylactic treatment with oral doxycycline
Yu, L. P., Smith, G. N., Brandt, K. D., Myers, S. L., O'Connor, B. L., & Brandt, D. A. (1992) · Arthritis & Rheumatism · doi:10.1002/art.1780351007 · Cited by 229
Tyler, J. A. (1985) · Biochemical Journal · doi:10.1042/bj2270869 · Cited by 224
The complete primary structure of human matrix metalloproteinase-3. Identity with stromelysin.
Saus, J., Quinones, S., Otani, Y., Nagase, H., Harris, E. D., & Kurkinen, M. (1988) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)68705-8 · Cited by 223
Balavoine, J. F., de Rochemonteix, B., Williamson, K., Seckinger, P., Cruchaud, A., & Dayer, J. M. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112669 · Cited by 205
Wooley, P. H., Whalen, J. D., Chapman, D. L., Berger, A. E., Richard, K. A., Aspar, D. G., & Staite, N. D. (1993) · Arthritis & Rheumatism · doi:10.1002/art.1780360915 · Cited by 204
CYTOKINES AND INFLAMMATION IN CARTILAGE DEGRADATION
Pelletier, J.-P., DiBattista, J. A., Roughley, P., McCollum, R., & Martel-Pelletier, J. (1993) · Rheumatic Disease Clinics of North America · doi:10.1016/s0889-857x(21)00331-8 · Cited by 189
Self-citationArthritis and Allied Conditions: A Textbook of Rheumatology
Shmerling, R. H. (1993) · Archives of Dermatology · doi:10.1001/archderm.1993.01680300160038 · Cited by 175
The Role of Tumor Necrosis Factor and Interleukin 1 in the Immunoinflammatory Response
Larrick, J. W., & Kunkel, S. L. (1988) · Pharmaceutical Research · doi:10.1023/a:1015904721223 · Cited by 153
Schwab, J. H., Anderle, S. K., Brown, R. R., Dalldorf, F. G., & Thompson, R. C. (1991) · Infection and Immunity · doi:10.1128/iai.59.12.4436-4442.1991 · Cited by 152
Myers, S. L., Dines, K. A., Brandt, D. A., et al. (1995) · PubMed · Cited by 134
Firestein, G. S., Berger, A. E., Tracey, D. E., et al. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.149.3.1054 · Cited by 128
Smith, R. J., Chin, J. E., Sam, L. M., & Justen, J. M. (1991) · Arthritis & Rheumatism · doi:10.1002/art.1780340112 · Cited by 113
Pelletier, J., Battista, J. A. D., Raynauld, J., Wilhelm, S., & Martel‐Pelletier, J. (1995) · PubMed · Cited by 108
Self-citationTaichman, R. S., & Hauschka, P. V. (1992) · Inflammation · doi:10.1007/bf00919342 · Cited by 108
van de Loo, F. A. J., Arntz, O. J., Otterness, I. G., & van den Berg, W. B. (1992) · PubMed · Cited by 92
PRIMER ON THE RHEUMATIC DISEASES
PART III Prepared by a Committee of the American Rheumatism Association (1959) · JAMA · doi:10.1001/jama.1959.73010300003015 · Cited by 89
Nguyen, Q. K., Mort, J. S., & Roughley, P. J. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115702 · Cited by 88
Pelletier, J.-P., McCollum, R., Jm, C., et al. (1995) · PubMed · Cited by 88
Self-citationVivien, D., Galéra, P., Lebrun, E., Loyau, G., & Pujol, J. ‐. (1990) · Journal of Cellular Physiology · doi:10.1002/jcp.1041430319 · Cited by 83
Matsukawa, A., Ohkawara, S., Maeda, T., Takagi, K., & Yoshinaga, M. (1993) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.1993.tb07967.x · Cited by 74
The interleukin-1 receptor antagonist and its delivery by gene transfer.
Evans, C. H., & Robbins, P. D. (1994) · PubMed · Cited by 40
Dingle, J. T., Horner, A. M., & Shield, M. (1991) · Cell Biochemistry and Function · doi:10.1002/cbf.290090206 · Cited by 37
Arner, E. C., Harris, R. R., Meo, T. M. D., Collins, R. C., & Galbraith, W. (1995) · PubMed · Cited by 30
Cited by
Role of proinflammatory cytokines in the pathophysiology of osteoarthritis
Kapoor, M., Martel-Pelletier, J., Lajeunesse, D., Pelletier, J.-P., & Fahmi, H. (2011) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2010.196 · Cited by 2,778
Self-citationThe Role of Inflammatory and Anti-Inflammatory Cytokines in the Pathogenesis of Osteoarthritis
Wojdasiewicz, P., Poniatowski, Ł. A., & Szukiewicz, D. (2014) · Mediators of Inflammation · doi:10.1155/2014/561459 · Cited by 1,608
Matrix Metalloproteinases: Role In Arthritis
Burrage, P. (2006) · Frontiers in Bioscience · doi:10.2741/1817 · Cited by 1,292
INTERLEUKIN-1 RECEPTOR ANTAGONIST: Role in Biology
Arend, W. P., Malyak, M., Guthridge, C. J., & Gabay, C. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.27 · Cited by 1,071
Pelletier, J.-P., Martel-Pelletier, J., & Abramson, S. B. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200106)44:6<1237::aid-art214>3.0.co;2-f · Cited by 1,072
Self-citation
Metadata
- Authors
- Caron, J. P., Fernandes, J. C., Martel‐Pelletier, J., Tardif, G., Mineau, F., Geng, C., & Pelletier, J.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 1996-09
- Volume
- 39
- Issue
- 9
- Pages
- 1535-1544
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2071823815
- Cited by
- 366
- References
- 38
- FWCI
- 10.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.